<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; Financial</title>
	<atom:link href="http://pharmaexecnews.com/category/financial/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Fri, 29 Apr 2011 14:00:12 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Berkshire Hathaway Picks up Lubrizol</title>
		<link>http://pharmaexecnews.com/biotechnology/berkshire-hathaway-picks-lubrizol/</link>
		<comments>http://pharmaexecnews.com/biotechnology/berkshire-hathaway-picks-lubrizol/#comments</comments>
		<pubDate>Tue, 22 Mar 2011 08:00:54 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11330</guid>
		<description><![CDATA[Berkshire Hathaway, a company owned by Warren Buffet, has announced this week that is all set to acquire Lubrizol for $9 billion in cash. Lubrizol is a specialty chemical company, and industry analysts are of the opinion that Buffet is buying the specialty chemical company to boost the earnings power of Berkshire Hathaway.

It seems that [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/berkshire-hathaway-picks-lubrizol/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fast Company Highlights 10 Top Innovators in Biotech</title>
		<link>http://pharmaexecnews.com/biotechnology/fast-company-highlights-10-top-innovators-biotech/</link>
		<comments>http://pharmaexecnews.com/biotechnology/fast-company-highlights-10-top-innovators-biotech/#comments</comments>
		<pubDate>Fri, 04 Mar 2011 08:00:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11214</guid>
		<description><![CDATA[Fast Company has surveyed the biotech world and come up with its list of the Top 10 companies in the industry. Amyris makes the list for its work combating the malaria parasite, while Galapagos and Fate Therapeutics get nods for pipeline innovation.

Most of the companies in the magazine&#8217;s Top 10 are relatively small, but biotech [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/fast-company-highlights-10-top-innovators-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Medco in-line Profit Report Fails to Excite Market</title>
		<link>http://pharmaexecnews.com/biotechnology/medco-inline-profit-report-fails-excite-market/</link>
		<comments>http://pharmaexecnews.com/biotechnology/medco-inline-profit-report-fails-excite-market/#comments</comments>
		<pubDate>Thu, 03 Mar 2011 14:00:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11243</guid>
		<description><![CDATA[Medco Health Solutions Inc&#8217;s (MHS.N) quarterly profit rose 11 percent on increased mail deliveries of generic drugs, but its shares fell as the report failed to excite investors.  The U.S. pharmacy benefit manager reported a fourth-quarter profit, excluding special items, that matched Wall Street&#8217;s target and it backed its 2011 forecast. Its shares fell 4.5 [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/medco-inline-profit-report-fails-excite-market/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Senators Resurrect Reimportation with New Bill</title>
		<link>http://pharmaexecnews.com/biotechnology/senators-resurrect-reimportation-bill/</link>
		<comments>http://pharmaexecnews.com/biotechnology/senators-resurrect-reimportation-bill/#comments</comments>
		<pubDate>Wed, 02 Mar 2011 14:00:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11240</guid>
		<description><![CDATA[Two U.S. senators have revived the reimportation debate with a new bill co-sponsored by a bipartisan group of their fellows. Sen. Debbie Stabenow (D-Michigan) is teaming up with Sen. Olympia Snowe (R-Maine) on the proposal, which would allow U.S. pharmacies and drug wholesalers to source products from other countries with &#8220;tough safety standards.&#8221;

Allowing importation from [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/senators-resurrect-reimportation-bill/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Top 10 Medical Device Venture Capital Deals of 2010</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/top-10-medical-device-venture-capital-deals-2010/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/top-10-medical-device-venture-capital-deals-2010/#comments</comments>
		<pubDate>Mon, 28 Feb 2011 08:00:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Devices and Technology]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11201</guid>
		<description><![CDATA[Fierce Medical Device&#8217;s first annual look at the top 10 VC deals of the year. Venture capital investment in the medical device industry fell 9 percent in 2010, ending the year as the fourth largest investment sector with $2.3 billion going into 324 deals. That&#8217;s up slightly over 2009, when medical devices ranked third among [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/top-10-medical-device-venture-capital-deals-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Obama&#8217;s Budget Delays Deep Cuts to Physician Payments</title>
		<link>http://pharmaexecnews.com/medical/healthcare-medical/obamas-budget-delays-deep-cuts-physician-payments/</link>
		<comments>http://pharmaexecnews.com/medical/healthcare-medical/obamas-budget-delays-deep-cuts-physician-payments/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 08:00:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11168</guid>
		<description><![CDATA[Although President Obama&#8217;s proposed $3.73 trillion budget for 2012 calls for more than $1 trillion in slashed spending, it protects doctors from steep cuts in their Medicare payments with a two year reprieve. The budget delays a scheduled 25 percent cut in the Sustainable Growth Rate, Medicare&#8217;s physician payment formula that was slated to go [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/medical/healthcare-medical/obamas-budget-delays-deep-cuts-physician-payments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Which Specialty Drugmakers Should Big Pharma Buy?</title>
		<link>http://pharmaexecnews.com/biotechnology/specialty-drugmakers-big-pharma-buy/</link>
		<comments>http://pharmaexecnews.com/biotechnology/specialty-drugmakers-big-pharma-buy/#comments</comments>
		<pubDate>Mon, 14 Feb 2011 08:00:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11160</guid>
		<description><![CDATA[Every so often, someone sets up a dartboard of likely targets for Big Pharma buyouts. This time, the target-setter is Barron&#8217;s, and the focus is on companies with market values of $10 billion or less. Most of them have at least one marketed product: &#8220;It&#8217;s less dangerous playing smaller outfits with approved drugs than those [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/specialty-drugmakers-big-pharma-buy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Copying Biotech Medicine Attracts More Drugmakers</title>
		<link>http://pharmaexecnews.com/biotechnology/copying-biotech-medicine-attracts-drugmakers/</link>
		<comments>http://pharmaexecnews.com/biotechnology/copying-biotech-medicine-attracts-drugmakers/#comments</comments>
		<pubDate>Tue, 01 Feb 2011 08:00:05 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11124</guid>
		<description><![CDATA[More drugmakers are seeing potential in the business of producing copycat versions of expensive biotechnology drugs as U.S. guidelines take shape. The topic was at the forefront of plans discussed by several executives at this week&#8217;s JP Morgan healthcare conference in San Francisco. Kevin Sharer, chief executive officer at Amgen Inc, said the world&#8217;s largest [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/copying-biotech-medicine-attracts-drugmakers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer Bungles Tax-Fueled Champix Surge</title>
		<link>http://pharmaexecnews.com/biotechnology/pfizer-bungles-taxfueled-champix-surge/</link>
		<comments>http://pharmaexecnews.com/biotechnology/pfizer-bungles-taxfueled-champix-surge/#comments</comments>
		<pubDate>Mon, 17 Jan 2011 08:00:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11078</guid>
		<description><![CDATA[A new cigarette tax and a stop-smoking drug were a match made in Japan, and it might have been heaven if Pfizer ($PFE) hadn&#8217;t fumbled. The drugmaker, which sells its Chantix remedy as Champix in Japan, knew the higher tax was coming, advertised its drug heavily, and then failed to make enough to satisfy demand.

As [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/pfizer-bungles-taxfueled-champix-surge/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Footstar  to acquire CPEX&#8217;s Drug-Delivery Technology</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/footstar-acquire-cpexs-drugdelivery-technology/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/footstar-acquire-cpexs-drugdelivery-technology/#comments</comments>
		<pubDate>Fri, 14 Jan 2011 08:00:29 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[Devices and Technology]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11074</guid>
		<description><![CDATA[A unit of Footstar Corp., a holding company, has agreed to acquire CPEX Pharmaceuticals for $76.6 million in cash. The bid is worth $27.25 a share&#8211;more than twice what it was a year ago as back-to-back quarterly profits helped fuel investor interest. CPEX focuses on what it calls a &#8220;drug delivery platform technology.&#8221; Platform, of [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/footstar-acquire-cpexs-drugdelivery-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

